The Insight Express Series explores how patient behavior shapes access, adherence, and long term treatment outcomes across the healthcare landscape. In this first series, IQVIA expert Luke Greenwalt breaks down the core drivers behind abandonment, adherence, persistence, and the growing impact of Medicare Part D policy changes. Each feature delivers clear, data grounded insights that help manufacturers, payers, and healthcare stakeholders understand how cost, coverage, and patient experience influence therapy decisions. From rising out of pocket costs to the effects of new Medicare caps, this series offers a concise, practical look at the trends reshaping patient behavior today.
Watch the series to gain actionable perspectives that support smarter planning, stronger patient engagement, and better forecasting. Register now to access every feature and stay ahead of the evolving dynamics that influence treatment access and outcomes.
Feature 1: Abandonment
When patients face higher out-of-pocket costs, they are less likely to fill their prescriptions. This trend is consistent across all brands, therapeutic classes, and payer channels. If a patient does not fill a payer-approved prescription, it is considered abandoned. This behavior influences insurers' benefit designs, access contracts, and demand capture strategies, and is a key consideration for policymakers aiming to assist patients.
Speaker: Luke Greenwalt, VP and Lead, U.S. Thought Leadership & Innovation, IQVIA
Feature 2: Adherence
As patients' out-of-pocket costs rise, their likelihood of continuing therapy in the first year (i.e., adherence) declines. This relationship holds across different diseases, products, and patient types. Factors such as competing therapies, patient demographics, support programs, and annual out-of-pocket caps, like Medicare Part D’s $2,000 max, all contribute to shaping patient adherence.
Speaker: Luke Greenwalt, VP and Lead, U.S. Thought Leadership & Innovation, IQVIA
Feature 3: One & Done
Persistence measures how long a patient continues a prescription, while “One and Done” describes those who fill only once and do not return. This can stem from price concerns, side effects, other health issues, dosing, effectiveness, demographics, or insurance coverage. Securing the initial fill is costly, but ensuring patients continue therapy is essential for better outcomes and accurate forecasting. If patients stop treatment early, they miss the potential benefits of therapy.
Speaker: Luke Greenwalt, VP and Lead, U.S. Thought Leadership & Innovation, IQVIA
Feature 4: Medicare Part D $2000 Cap
Big changes are coming to Medicare Part D. Following the removal of catastrophic phase cost-sharing in 2024, a new $2,000 annual out-of-pocket cap takes effect in 2025. This major policy shift has the potential to reshape patient behavior as the reduced financial burden are expected to reduce prescription abandonment, improve treatment initiation rates, and enhance long-term adherence.
Speaker: Luke Greenwalt, VP and Lead, U.S. Thought Leadership & Innovation, IQVIA
Feature 5: Medicare Part D $0 Out-of-Pocket
How is the $2,000 Medicare Part D cap that began this year reshaping speciality treatment access? Dive deeper into its impact on oncology with trends from recent years as changes from the Inflation Reduction Act took effect. Patients are seeing improved access, but the ripple effects matter for other key stakeholders, too.
Speaker: Luke Greenwalt, VP and Lead, U.S. Thought Leadership & Innovation, IQVIA
Related solutions
Data, AI, and expertise empower Commercial Solutions to optimize strategy, accelerate market access, and maximize brand performance.
Grow your brand, now and through patent expiry
Gain high value access and increase the profitability of your brands